Morphogenesis, CohBar Announce Acceptance of Abstract For Poster Presentation At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Morphogenesis and CohBar have announced the acceptance of an abstract for a poster presentation at the 2023 ASCO Meeting. The companies recently entered into a definitive merger agreement for an all-stock transaction to form TuHURA Biosciences, Inc., which will trade on Nasdaq. The transaction is expected to close in Q3 2023.
May 30, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CohBar's merger with Morphogenesis to form TuHURA Biosciences, Inc. is expected to close in Q3 2023, and the combined company will trade on Nasdaq.
The merger between CohBar and Morphogenesis will create a combined company with a late-stage oncology pipeline, which could potentially increase the value of the company. The news of the presentation at the 2023 ASCO Meeting also highlights the progress of their research, which may positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100